文献速递头颈外科

新辅助化疗增强HPV相关口咽癌患者的肿瘤特异性T细胞免疫

Neoadjuvant chemotherapy enhances tumor-specific T cell immunity in patients with HPV-associated oropharyngeal cancer.
PubMed 文献 · Head Neck · 2023-07-21

本研究探讨新辅助化疗(NAC)对新诊断HPV相关口咽鳞状细胞癌(OPSCC)患者肿瘤浸润淋巴细胞(TILs)中HPV特异性T细胞应答的影响。采用自体共培养法检测10例经PCR证实HPV16阳性患者NAC前后的HPV特异性TIL应答,发现8例(80%)在NAC后出现更强的HPV16特异性TIL应答,且HPV特异性TIL应答净负向变化与疾病复发显著相关(p=0.04,Mann-Whitney检验),而手术时病理完全缓解与复发无相关性。结论认为NAC可诱导新诊断HPV相关OPSCC患者的HPV特异性肿瘤T细胞应答,而NAC后无应答增强可能与复发风险相关。

要点

  • NAC后8/10例(80%)HPV16阳性OPSCC患者出现更强的HPV16特异性TIL应答,部分为多克隆。
  • HPV特异性TIL应答净负向变化与疾病复发显著相关(p=0.04,Mann-Whitney检验)。
  • 手术时病理完全缓解与复发无相关性。

核心结论

  • NAC可诱导新诊断HPV相关OPSCC患者的HPV特异性肿瘤T细胞应答;NAC后缺乏应答增强可能与复发风险相关。

研究设计与样本

  • 研究纳入新诊断HPV相关OPSCC患者,采用自体共培养法检测NAC前后肿瘤浸润淋巴细胞(TILs)的HPV特异性应答。
  • 共检测10例经PCR证实HPV16阳性肿瘤患者NAC前后的HPV特异性TIL应答。

主要发现

  • 10例PCR证实HPV16阳性肿瘤患者中,8例(80%)在NAC后观察到比NAC前更强的HPV16特异性TIL应答,部分为多克隆。
  • HPV特异性TIL应答净负向变化与疾病复发显著相关(p=0.04,Mann-Whitney检验)。
  • 手术时病理完全缓解与复发无相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) with neoadjuvant chemotherapy (NAC) results in a high rate of 5-year recurrence free survival with few patients requiring adjuvant treatment. We hypothesized that NAC enhances primary tumor HPV-specific T cell responses. METHODS: HPV-specific responses in tumor infiltrating lymphocytes (TILs) before and after NAC were determined using autologous co-culture assays. RESULTS: Greater HPV16-specific TIL responses, sometimes polyclonal, were observed after NAC compared to before in 8 of 10 patients (80%) with PCR-verified HPV16-positive tumors. A significant association was observed between net-negative change in HPV-specific TIL response and disease relapse (p = 0.04, Mann-Whitney test), whereas pathologic complete response at time of surgery did not correlate with recurrence. CONCLUSIONS: NAC induces HPV-specific tumor T cell responses in patients with newly diagnosed HPV-associated OPSCC; whereas lack of an increase following NAC may associate with risk of relapse.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Samaniego C, Friedman J, Yang X, et al. Neoadjuvant chemotherapy enhances tumor-specific T cell immunity in patients with HPV-associated oropharyngeal cancer. Head Neck. 2023. PMID: 37480219. doi:10.1002/hed.27463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。